Published in J Immunol on January 08, 2010
Imaging of vascular development in early mouse decidua and its association with leukocytes and trophoblasts. Biol Reprod (2012) 1.11
New insights into IL-12-mediated tumor suppression. Cell Death Differ (2014) 1.09
Diversity through phosphine catalysis identifies octahydro-1,6-naphthyridin-4-ones as activators of endothelium-driven immunity. Proc Natl Acad Sci U S A (2011) 0.98
Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother (2013) 0.96
The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity. Immunol Rev (2014) 0.91
Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology (2013) 0.85
Induction of Th1Immune responses following laser ablation in a murine model of colorectal liver metastases. J Transl Med (2011) 0.78
Radiation therapy combined with Listeria monocytogenes-based cancer vaccine synergize to enhance tumor control in the B16 melanoma model. Oncoimmunology (2014) 0.76
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A (1995) 7.11
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature (2006) 7.01
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (1997) 6.37
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature (2008) 5.15
Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science (1998) 5.07
The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A (2007) 4.52
Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A (2007) 4.27
Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med (1993) 4.04
Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1998) 3.72
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol (1999) 3.09
Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med (1994) 3.02
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 2.68
VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol (1997) 2.43
Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol (2000) 2.24
The role of interleukin 12 in the immune response, disease and therapy. Immunol Today (1994) 2.24
Interleukin-12. J Leukoc Biol (1994) 2.22
Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood (1996) 2.09
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer (1999) 1.97
A novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells. J Immunol (1991) 1.92
Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood (2000) 1.76
Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res (2007) 1.73
Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity (1998) 1.49
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol (1989) 1.46
Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res (2006) 1.39
Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res (2000) 1.38
Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol (2003) 1.38
Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma. Cancer Res (2002) 1.20
Distribution and characterization of GFP(+) donor hematogenous cells in Twitcher mice after bone marrow transplantation. Am J Pathol (2000) 1.18
Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol (1995) 1.17
VEGFR-3 in adult angiogenesis. J Pathol (2001) 1.13
Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts. Br J Cancer (2003) 1.07
VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood (2000) 1.05
Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12. Cancer Res (1997) 1.04
IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer (1998) 1.03
Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis. J Immunol (2009) 1.03
A comparison of efficacy and specificity of three NK depleting antibodies. J Immunol Methods (1996) 1.02
Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol Ther (2008) 1.00
Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell Immunol (1995) 0.96
Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochem Biophys Res Commun (2004) 0.93
Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer (1995) 0.90
Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma. J Immunol (2003) 0.90
VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels. Pathol Res Pract (2005) 0.89
Clinical use of systemic IL-12 therapy. Cancer Chemother Biol Response Modif (2001) 0.83
IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters. Biotechnol Ther (1992) 0.82
Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor. J Immunol (1991) 0.81
Phase I trial of interleukin-2 plus gamma-interferon. J Immunother (1991) (1992) 0.79
Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity. Int J Cancer (2003) 0.79
Antigenic profiles of individual-matched pairs of primary and melanoma metastases. Hum Pathol (2009) 0.77
A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol (2006) 12.13
Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol (2008) 9.24
Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A (2007) 6.08
Two RNAi complexes, RITS and RDRC, physically interact and localize to noncoding centromeric RNAs. Cell (2004) 4.34
Optimization and use of peptide mass measurement accuracy in shotgun proteomics. Mol Cell Proteomics (2006) 4.25
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol (2005) 4.18
The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods (2005) 3.71
Large-scale phosphorylation analysis of alpha-factor-arrested Saccharomyces cerevisiae. J Proteome Res (2007) 3.13
Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A (2008) 3.03
Steps in assembly of silent chromatin in yeast: Sir3-independent binding of a Sir2/Sir4 complex to silencers and role for Sir2-dependent deacetylation. Mol Cell Biol (2002) 2.93
A proteomic strategy for gaining insights into protein sumoylation in yeast. Mol Cell Proteomics (2004) 2.58
Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells. Sci Signal (2011) 2.33
Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A (2005) 2.23
The impact of peptide abundance and dynamic range on stable-isotope-based quantitative proteomic analyses. J Proteome Res (2008) 2.11
Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol (2008) 1.93
Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracy instrumentation. J Proteome Res (2006) 1.82
Quantitative proteomics reveals a dynamic interactome and phase-specific phosphorylation in the Neurospora circadian clock. Mol Cell (2009) 1.80
INF2 is an endoplasmic reticulum-associated formin protein. J Cell Sci (2009) 1.67
Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol (2006) 1.61
Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum Immunol (2009) 1.53
Characterization of mouse spleen cells by subtractive proteomics. Mol Cell Proteomics (2005) 1.51
Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells. Genes Dev (2010) 1.46
MMFPh: a maximal motif finder for phosphoproteomics datasets. Bioinformatics (2012) 1.44
Rapid and reproducible single-stage phosphopeptide enrichment of complex peptide mixtures: application to general and phosphotyrosine-specific phosphoproteomics experiments. Anal Chem (2011) 1.40
Budding yeast silencing complexes and regulation of Sir2 activity by protein-protein interactions. Mol Cell Biol (2004) 1.37
Absolute quantification of protein and post-translational modification abundance with stable isotope-labeled synthetic peptides. Nat Protoc (2011) 1.34
The majority of the Saccharomyces cerevisiae septin complexes do not exchange guanine nucleotides. J Biol Chem (2003) 1.29
Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. PLoS One (2011) 1.13
Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol Res (2009) 1.11
Imaging of vascular development in early mouse decidua and its association with leukocytes and trophoblasts. Biol Reprod (2012) 1.11
Plk1 regulates the kinesin-13 protein Kif2b to promote faithful chromosome segregation. Mol Biol Cell (2012) 1.10
Insulin-stimulated GLUT4 protein translocation in adipocytes requires the Rab10 guanine nucleotide exchange factor Dennd4C. J Biol Chem (2011) 1.07
Transcriptional interference among the murine beta-like globin genes. Blood (2006) 1.06
Quorum sensing: dynamic response of Pseudomonas aeruginosa to external signals. Trends Microbiol (2006) 1.05
Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition. Structure (2013) 1.03
Rapid determination of multiple linear kinase substrate motifs by mass spectrometry. Chem Biol (2012) 1.01
MacroSEQUEST: efficient candidate-centric searching and high-resolution correlation analysis for large-scale proteomics data sets. Anal Chem (2010) 1.01
Yeast Chfr homologs retard cell cycle at G1 and G2/M via Ubc4 and Ubc13/Mms2-dependent ubiquitination. Cell Cycle (2007) 0.97
Antibody-labeled fluorescence imaging of dendritic cell populations in vivo. J Biomed Opt (2008) 0.97
Migration of skin dendritic cells in response to ionizing radiation exposure. Radiat Res (2009) 0.97
Exposure to ionizing radiation induces the migration of cutaneous dendritic cells by a CCR7-dependent mechanism. J Immunol (2012) 0.97
Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother (2013) 0.96
The Tlo proteins are stoichiometric components of Candida albicans mediator anchored via the Med3 subunit. Eukaryot Cell (2012) 0.95
Activation of heat shock protein 70 promoter with meso-tetrahydroxyphenyl chlorin photodynamic therapy reported by green fluorescent protein in vitro and in vivo. Photochem Photobiol (2003) 0.94
Optogenetic control of chemokine receptor signal and T-cell migration. Proc Natl Acad Sci U S A (2014) 0.93
IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol (2013) 0.91
Multisite phosphorylation of the guanine nucleotide exchange factor Cdc24 during yeast cell polarization. PLoS One (2009) 0.90
G-protein-coupled receptor-2-interacting protein-1 is required for endothelial cell directional migration and tumor angiogenesis via cortactin-dependent lamellipodia formation. Arterioscler Thromb Vasc Biol (2013) 0.90
In vivo study of T-cell responses to skin alloantigens in Xenopus using a novel whole-mount immunohistology method. Transplantation (2007) 0.89
Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets. Immunology (2011) 0.88
Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha. Mol Cancer Ther (2006) 0.88
Tempest: GPU-CPU computing for high-throughput database spectral matching. J Proteome Res (2012) 0.88
Insulin stimulates the phosphorylation of the exocyst protein Sec8 in adipocytes. Biosci Rep (2009) 0.88
Emerging themes in uterine natural killer cell heterogeneity and function. Am J Reprod Immunol (2012) 0.87
Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS. Mol Immunol (2009) 0.87
Increasing phosphoproteomic coverage through sequential digestion by complementary proteases. Anal Bioanal Chem (2011) 0.86
Radio-responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors. Int J Cancer (2013) 0.86
Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. Biochemistry (2011) 0.85
Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology (2013) 0.85
Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag. Vaccine (2006) 0.85
Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors. Hum Gene Ther (2007) 0.84
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol (2014) 0.84
An implantable vascularized protein gel construct that supports human fetal hepatoblast survival and infection by hepatitis C virus in mice. PLoS One (2010) 0.83
Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics (2013) 0.83
Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine (2007) 0.82
Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model. Cancer Immun (2013) 0.82
Characterization of a lymph node within the mouse prostate: Detailed analysis using whole mount histology. Prostate (2005) 0.81
Visualizing the Mechanism of Epoxide Hydrolysis by the Bacterial Virulence Enzyme Cif. Biochemistry (2016) 0.80
Generation of a dual-functioning antitumor immune response in the peritoneal cavity. Am J Pathol (2013) 0.80
Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors. Prostate (2002) 0.80
Thioredoxin reductase is inhibited by the carbamoylating activity of the anticancer sulfonylhydrazine drug laromustine. Mol Cell Biochem (2012) 0.79
Imaging enzyme activity with polarization-sensitive confocal fluorescence microscopy. J Microsc (2004) 0.79
Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity. Int J Cancer (2003) 0.79
A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens. J Immunol Methods (2011) 0.78
Interleukin-12 preserves the cutaneous physical and immunological barrier after radiation exposure. Radiat Res (2015) 0.78
SILAC surrogates: rescue of quantitative information for orphan analytes in spike-in SILAC experiments. Anal Chem (2013) 0.76